Is Thymosin Alpha-1 Legal in Texas? How to Access It Legally

What Is Thymosin Alpha-1 and Why Does Its Legal Status Matter?

Thymosin Alpha-1 is a 28-amino-acid peptide derived from thymosin fraction 5, first isolated from bovine thymus tissue by Allan Goldstein at George Washington University in the early 1970s. The synthetic version, sold commercially as Zadaxin in more than 35 countries, modulates T-cell activity and has been studied in hepatitis B, hepatitis C, sepsis, and several immunodeficiency states. 1

In the United States, TA-1 has no FDA-approved indication. That single fact shapes everything about how Texas patients and physicians interact with it legally.

Why FDA Approval Status Drives State-Level Access

Because TA-1 is not an approved drug, it cannot be dispensed from a standard retail pharmacy. Access instead flows through one of two federal compounding pathways, 503A or 503B, both established under the Drug Quality and Security Act of 2013 (DQSA). 2

The FDA regulates which bulk drug substances compounders may use. A substance placed on the FDA's "Category 2" list (drugs that raise safety concerns) may not be compounded under 503A. A substance on the "Category 1" list may be compounded freely. TA-1 currently sits in a review queue with no final categorical placement, creating a conditional gray area that clinicians must understand before prescribing. 3

The Clinical Trial Record That Supports Physician Interest

Interest in TA-1 is not speculative. A randomized controlled trial published in the Journal of Hepatology (N=75) found that TA-1 combined with interferon-alpha produced a sustained virologic response in 31% of hepatitis B patients vs. 13% with interferon alone (P<0.05). 4 A separate meta-analysis covering 11 RCTs (N=1,012) concluded that TA-1 significantly improved 28-day survival in patients with sepsis (risk ratio 0.79, 95% CI 0.68 to 0.92). 5 These findings give licensed physicians a defensible clinical basis for off-label compounded prescribing, particularly for immune-compromised patients.

Federal Law Framework: FDA Bulk Substances and Compounding Pathways

Federal law sets the floor. Texas cannot make TA-1 more freely available than federal rules allow.

Section 503A: Patient-Specific Compounding

Under 21 U.S.C. § 353a, a licensed pharmacist or physician may compound a drug for an identified patient from a bulk drug substance if the substance: (1) is not on the FDA's list of substances that may not be compounded, (2) is compounded pursuant to a valid prescription, and (3) meets United States Pharmacopeia (USP) or National Formulary monograph standards where applicable. 6

TA-1 does not currently appear on the FDA's "negative" bulk-substances list for 503A compounders. Its review is ongoing. That means a 503A pharmacy can still compound TA-1 today, provided all other conditions are met. Physicians and patients relying on this pathway should recognize that the FDA could move TA-1 to Category 2 at any future review cycle, which would immediately prohibit 503A compounding.

Section 503B: Outsourcing Facilities

503B outsourcing facilities may compound TA-1 only if the substance appears on the FDA's 503B bulks list. 7 As of July 2024, TA-1 is not on the 503B approved bulks list. 503B facilities therefore may not compound TA-1 for office stock or distribution to healthcare providers without a patient-specific prescription tying back to 503A standards. This is a meaningful practical constraint: patients cannot receive TA-1 from a hospital formulary or from an outsourcing facility's standard catalog.

FDA Enforcement Discretion

The FDA has exercised enforcement discretion on several peptides historically, but that discretion is not guaranteed and does not constitute legal approval. The agency's 2023 guidance update on compounded peptides signaled increased scrutiny of bulk peptide substances, particularly those sourced from overseas API manufacturers. 8 Physicians prescribing TA-1 should verify their compounding pharmacy sources active pharmaceutical ingredient (API) domestically or from an FDA-registered foreign facility.

Texas State Law: TSBP and Texas Medical Board Rules

Texas does not have a separate statute that specifically addresses Thymosin Alpha-1. Access is instead governed by the intersection of federal compounding law and two Texas regulatory bodies.

Texas State Board of Pharmacy (TSBP)

The TSBP licenses and inspects all pharmacies operating in Texas. Compounding pharmacies must comply with Texas Administrative Code Title 22, Part 15, Chapter 291, Subchapter E (Non-Sterile Compounding) and Subchapter F (Sterile Compounding), which incorporate USP <797> standards for sterile preparations. 9 TA-1 is administered by subcutaneous injection, meaning any Texas pharmacy compounding it must hold a sterile compounding license and comply with USP <797> beyond-use dating and environmental monitoring requirements.

A pharmacy compounding TA-1 without a sterile compounding license is operating outside TSBP rules. Patients should confirm a pharmacy's TSBP license type before accepting a compounded TA-1 product.

Texas Medical Board and Prescribing Standards

The Texas Medical Board (TMB) governs physician practice under Texas Occupations Code Chapter 155. Off-label prescribing of compounded preparations is legally permissible in Texas as long as the physician documents a legitimate medical purpose, obtains informed consent, and exercises sound clinical judgment consistent with the standard of care. 10

The TMB's rule on pain management and controlled substances (22 TAC §170.3) requires a proper patient evaluation, but that framework applies broadly to all prescribing. For TA-1, a physician should document: baseline immune labs (CD4/CD8 ratio, NK cell activity, CBC), clinical indication (e.g., recurrent viral infections, hepatitis B adjunct), informed consent noting investigational status, and a monitoring plan.

Telehealth Prescribing in Texas

Texas Senate Bill 670 (2017) and subsequent TMB telehealth rules allow a physician to prescribe a compounded medication following a synchronous audio-video evaluation, provided a proper patient-provider relationship exists. 11 HealthRX and similar telehealth platforms may therefore prescribe TA-1 to Texas patients after a full clinical evaluation conducted via video. An initial phone-only evaluation does not satisfy TMB requirements for establishing a new patient relationship for prescribing purposes.

How to Get Thymosin Alpha-1 Legally in Texas: Step-by-Step

Getting TA-1 legally in Texas requires several sequential steps. Skipping any one of them exposes both patient and prescriber to legal and safety risk.

Step 1: Establish Care With a Licensed Texas Physician

The patient must see a physician (MD or DO) licensed in Texas who has reviewed relevant labs, assessed the clinical indication, and determined that TA-1 is appropriate. A nurse practitioner may prescribe in Texas under collaborative practice agreements, but the supervising physician remains responsible under TMB rules.

Step 2: Obtain a Patient-Specific Written Prescription

The physician issues a prescription naming: the patient, the compound (Thymosin Alpha-1, typically 1.6 mg per dose), the concentration (often 10 mg/mL in bacteriostatic water after reconstitution), route (subcutaneous), frequency, and quantity. 12 General "standing orders" for TA-1 without patient-specific prescriptions do not satisfy 503A requirements.

Step 3: Select a TSBP-Licensed Sterile Compounding Pharmacy

The prescription must go to a pharmacy that holds an active TSBP sterile compounding license. Patients can verify license status on the TSBP license search portal. The pharmacy must also obtain TA-1 API from an FDA-registered manufacturer or supplier, not from unregistered overseas vendors. 13

Step 4: Verify the Pharmacy's API Sourcing and Certificate of Analysis

A reputable compounding pharmacy provides a Certificate of Analysis (CoA) for each lot of TA-1 API, confirming purity, identity, and sterility. Patients receiving TA-1 without a CoA available upon request are accepting an unknown product. This is not a formality, a 2012 fungal meningitis outbreak traced to a compounding pharmacy's contaminated methylprednisolone killed 64 people across 20 states, according to the CDC. 14 Quality controls at compounding pharmacies are not optional.

Step 5: Follow the Prescribed Administration Protocol

Standard clinical use of TA-1 studied in trials involves 1.6 mg subcutaneous injection two to three times weekly for 6 to 12 weeks, though protocols vary by indication. 15 Patients should inject into subcutaneous tissue (abdomen or thigh), rotate sites, and store unused vials at 2 to 8°C. Reconstituted solution should be used within 14 days per USP <797> beyond-use dating guidelines for Category 1 sterile compounds. 16

Clinical Evidence Summary: What the Trials Actually Show

TA-1's evidence base is meaningful but limited by U.S. Standards. Most large trials were conducted in Asia and Eastern Europe, where Zadaxin is approved. Understanding what the data actually show helps physicians and patients set accurate expectations.

Hepatitis B and C

The most cited RCT is the Italian multicenter trial published in Hepatology (1993), in which TA-1 plus interferon-alpha produced a 40% complete response rate in chronic hepatitis B vs. 18% with interferon alone (N=108, P<0.02). 17 For hepatitis C, a Phase III RCT found no significant improvement in sustained virologic response when TA-1 was added to pegylated interferon plus ribavirin, suggesting the benefit may be interferon-specific. 18

Sepsis and Critical Illness

The meta-analysis by Wu et al. (2015, N=1,012 across 11 RCTs) found a statistically significant reduction in 28-day mortality (RR 0.79, 95% CI 0.68 to 0.92, P<0.001) with TA-1 in sepsis patients. 5 These trials used intravenous or subcutaneous TA-1 at 1.6 mg twice weekly. The quality of individual trials was moderate by GRADE criteria.

Immune Reconstitution and HIV

A pilot study (N=30) in HIV patients not responding to antiretroviral therapy found that TA-1 (1.6 mg subcutaneous, twice weekly for 12 weeks) increased CD4 cell counts by a mean of 47 cells/mm3 vs. 9 cells/mm3 in placebo (P=0.04). 19 Larger confirmatory trials have not been completed in the U.S.

Cancer Immunotherapy Adjunct

Preliminary data from a Chinese multicenter RCT (N=200) showed improved 1-year survival in non-small cell lung cancer patients receiving TA-1 alongside chemotherapy (58% vs. 41%, P=0.03). 20 These results have not been replicated in FDA-registration-quality trials, and TA-1 is not part of any NCCN guideline as of 2024.

Risks, Limitations, and What Physicians Must Disclose

TA-1 has a favorable reported safety profile. In a pooled analysis of 1,163 patients across hepatitis and sepsis trials, the most common adverse events were injection-site reactions (8.2%) and transient fatigue (5.4%); serious adverse events occurred in 1.1% of patients. 21 No genotoxicity signals have been reported in preclinical studies. 22

Still, the physician must disclose the following before prescribing:

• TA-1 is not FDA-approved in the United States.
• Long-term safety data from U.S. Populations are lacking.
• Compounded products are not subject to the same manufacturing oversight as FDA-approved drugs.
• The legal status of TA-1 compounding could change if the FDA reclassifies it.
• Insurance does not cover compounded TA-1; patients pay out of pocket, typically $150, $400 per month depending on the compounding pharmacy and dose.

The Endocrine Society's 2020 position statement on compounded hormone and peptide therapies states: "Patients must be informed that compounded preparations have not been evaluated by the FDA for safety, efficacy, or quality, and that the evidence base for many compounded peptides remains limited." 23

Distinguishing Legal Sources From Gray-Market TA-1

A significant volume of TA-1 is sold online as a "research chemical" for "laboratory use only." These products are:

• Not intended for human use under federal law.
• Not compounded under USP <797> or cGMP standards.
• Not subject to TSBP oversight.
• Of unknown purity and sterility.

Purchasing TA-1 from these sources and self-injecting it is illegal under Texas Health and Safety Code §483 (Dangerous Drugs), which prohibits possession of a prescription drug without a valid prescription. 24 Physicians who direct patients to research-chemical vendors face TMB disciplinary action and potential federal prosecution under the FDCA.

The only legally compliant path in Texas is the physician prescription combined with a TSBP-licensed 503A sterile compounding pharmacy.

Practical Checklist for Texas Patients Seeking TA-1

Patients asking their physician about TA-1 in Texas should confirm each of the following before beginning therapy:

• The prescribing physician holds an active Texas medical license (verify at tmb.state.tx.us).
• A full clinical evaluation was completed, including relevant labs and documented indication.
• A patient-specific written prescription was issued for the compounded preparation.
• The dispensing pharmacy holds an active TSBP sterile compounding license (verify at pharmacy.texas.gov).
• The pharmacy provides a Certificate of Analysis for the TA-1 lot dispensed.
• The physician has documented informed consent noting investigational status and lack of FDA approval.
• A follow-up visit is scheduled at 6 to 8 weeks to assess clinical response and tolerability. 25

Texas patients may also request that their compounding pharmacy confirm in writing that it sources TA-1 API from an FDA Drug Master File (DMF)-registered supplier. The FDA maintains a public DMF database that pharmacy staff can reference. 26